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-1INTRODUCTION AND PUP..POSE

Iron deficiency states are frequently encountered in clinical practice.

All aspects of the situation have been studied for years.

Never-

. theless, even some of the fundamental knowledge about iron metabolism
. .
1,2 '!.T~th
is in dispute or has undergone revunon
in th
• e recen t ·o,aot.
_ '"
rv .....
such a fluctuating body of knowledge, it is not difficult to understand
why the crnrunercial market has been flooded with a variety of iron preparat ions each purporting to have advantages either in efficacy or' in a lower
incidence of toxicity.

The purpOIBEl of this paper, after a brief review

of iron metabolism ana history of iron therapy, is to present a more
detailed analysis of one of the most interesting prepqrations---IronDextran (Imferon)R.
IRON HETABOLISt1

A comprehensive review of the many facets of iron metabolism will
not be attempted here.

Many excellent reviews and books on the subject

have been published in the recent past. 1,2,3,4,$
Certain disorders can cause pathological changes in ferrokinetics
and iron storage, i.e., pulmonary hemosiderosis, intravascular hemolysis,
Laennec's cirrhosis., etc., without affecting total body iron content to
any &,Teat extent. 1 However, the most frequently encountered abnormalities related to iron metabolism are related to either an excess or deticiency of total body iron.

Thus, any discussion of iron metabolism must

focus on factors relating to accUc'nulation

~md

excretion of iron by the

body. (Fig. 1)
Iron exeretion--As

a

metabolit~

is greatly limited.

iron is somewhat unique in that the excretory route
This feature of its metabolism has such important

implications with regard to the clinical use of iron, particularly

-2-

parenteral iron, that it will be dealt with first.
In

h~~ns,

approximately one-third of body iron excretion occurs

in the feces and two-thirds is lost from the skin.

Very little iron

is excreted normally in the urine (less than 0.1 mg. per day).

Urinary

iron loss following parenteral iron therapy is of some interest and will
be discussed later.
In the past it
iron.

'-laS

felt that t,lle colon could actively excrete excess

Balance studies as long ago as 1938 indicated that the body has

no inherent capacity to excrete excess iron into the gastointestinal
tract. 4 Radioisotope studies indicate that most of the iron found in
the feces represents only unabsorbed iron from the diet. 4 Total fecal
iron loss including that from microscopic blood loss and des«iPamated
intestinal m1.1cosal cells in mormal adult human ,subjects has been calculated at approximately O.4mg/day. 4
Total daily iron excretion is not completely fixed.

Host cells

contain iron somewhat in proportion to the quantity of iron in body
stores. 1

This provides for a lim.i ted selective excretion of iron in

daily obligatory loss of cells and secretions.

F'or example, after

blood transfusions have caused excessive iron stores, excretion of iron
exceeds absorption by about 4 mg. per day in an effort to reestablish
normal body iron equilibrium. 1
Normal daily excretion in the h'llinan male probably does not exceed
1 to 2 mg. per day.

In the female, where most cases of iron-deficiency

in this country are encountered, additional losses are incurred through
menstruation, pregnancy, and

]a

cta.tion.

In the menstruating female,

an additional 0.3 to 1 mg. per day is required.

r'regnaney demands

another 2 mg. per day for the duration of gestation and lactation. 3

-3The total extra iron loss to the mother is at least 500 lng. attributed
to the fetus, placenta, and blood loss at delivery. 6,7
Except for the increased loss of iron in females as noted above,
the restricted loss of iron from the body is explained by the intracellular location of most of the iron either in tissue stores of incorporated in hemoglobin and by the tight chelation by transferrin of that
small fraction in transit through the plasma. (Fig. 1)
It is
L~fluence

L~portant

to know whether parenterally injected iron compounds

the normal excretion of iron.

Tnis Will be discussed later.

Iron absorption--Iron absorption from the gastrointestinal tract is regulated by
factors in tr.ree anatomic locations.

Intraluminal factors include ana-

t~nic abnormalities, dietary constituents, and intestinal secretions. 1,2,4
(Table 1)
Interest in mucosal cell factors has centered around the presence
or absence of a ltmucosal block" initially proposed by Granick. 8 According to this theory, iron absorption was regulated by an iron-accepting
protein of the intestinal mucosal cell called apoferritin.
recent '!lOrk causes some objections to this theory • .3

However,

It is now felt

that iron either in ionic form or in a low molecular weight complex
crosses the mucosal cell to the vascular border, where it is transferred
to the plasma by an oxidative process which appears to be the rate lim.i ting reaction.

Iron that is not rapidly transferred to plasma is complexed

with apoferritin to form ferritin, a form of storage iron.

In this con-

cept, the apoferritin has no direct regulating affect on iron absorption.
The third anatomic location exerting some regulatory influence on
iron absorption from the gut is corporeal with reference especially to
the demands of erythropoiesis and the tissue iron stores.

-).+-

The factors regulating iron absorption are very complex and
our understanding of their interrelationships is somewhat less than
complete
Iron transport--At anyone time there is normally only about 3-4 mg. of iron in
the plasma.

Most of the iron entering the plasma is derived from the

reticuloendothelial system following breakdown of hemoglobin and the
major portion leaving the plasma is directed to the bone marrow for
hemoglobin synthesis.

4,9

Iron released from tissue stores, tissue

enzymes, and the gut also contributes to the plasma iron pool, although
to a much lesser extent.

In the plasma it is bound to a protein called

transferrin which is :nade in the liver and has the electrophoretic
mobility of a Beta-l globulin. 4 It is normally present in the plasTIl2.
in a concentration sufficient to bind 280-400 meg. of iron per 100 ml.
of plasma.

Normally only one-third of the transferrin is bound to iron.

Iron storage--Storage iron in the normal adult comprises about 20-25 per cent of
the total body iron.

Phlebotomy studies by Pritchard revealed tl,:,e aver-

a.ge iron stores in normal adult males to be 819 mg. while those in
normal nulliparous women were only

254 mg. 10

During the course of normal pregnancy 'there is an LDcrease in red
blood cell volume and plasma volume. 6,11 The latter is §,Teater them
the former so IIhydremia fl develops with a decreased red blood cell count
and hemoglobin concentration.

The majority of workers consider this

finding as physiological. 6 Others have presented evidence that adequate iron stores 'Ifill almost completely prevent this oecurence. 11
They point out that the Bantu Negroes in South Africa, who display

-5tissue siderosis resulting from excessive dietary iron, rarely have
a decrease in hemoglobin concentration during pregnancy.
Iron stores exist as an intracellular iron-protein complex in
two different forms.

Normally the largest portion is stored as ferritin

( 60 to 70 per cent ) which is water soluble and cannot be demonstrated
by staining methods for iron. 2 The rest of the iron is stored as hemosiderin which is water insoluble, stainable and thought to be less readily available than ferritin.

In cases of microcytic, hypockromie anemias

examination of marrow for hemosiderin has proved to be a reliable method
for evaluating iron stores and establishing a diagnosis of iron-deficiency
anemia.
Most of the ferritin in the body is located in the reticuloendothelial and parenchymal cells of the liver and spleen.

During iron over-

load other parenchymal cells contain significant quantities of iron.
(This will be discussed further in a later section.)
Ferrokinetics--Radioisotopic methods have added sTeatly to our knowledge of iron
metabolism.

Such stUdies have allo;'led us to measure iron turnover rates

and to appreciate the relative importance and dynamic status of the
various metabolic circuits.
The half time of plasma clearance of iron is 60 to 120 minutes and
the total iron turnover is 20 to 40 mg. per day. 2,3,12

In the normal

adult male about 21 mg. of iron Der day is utilized and released by
hemoglobin metabolism. 2 (Fig. 1) Actual human ferrokinetics are more
complex than is indicated by the brief description above.

An integro-

differential mathematical analysis of the data indicates that there are
both slow and fast components of iron leaving and entering the plasma. 12

-6REVIEttl OF HISTORY OF PARENTERAL IRON Tl'::ERAPY

The efficacy of oral iron therapy in iron-deficiency anemia
has been well substantiated in the literature.

Most workers have

found that in the majority of cases the rate of hemoglobin regeneration is nearly the same using either oral or parenteral iron prepar·
6,10,13,14 Some
.
a t l.ons.
... wor kers, 1:1. owever, have repor t e d t,1"lat th"Joe rl.se
in hemoglobin after parenteral iron is "double" that of the orally
treated patients.

15

After the hemoglobin mass has returned to normal

with oral iron therapy, several more months of continuous iron therapy
are required to bring about full restoration of the depleted iron stores. 10,16
There are other problems with oral iron therapy.

In one study on the

effects of iron on pregnant women gastrointestinal side effects such as
constipation, nausea, abdominal pain and diarrhea occured in
per cent of patients. 13

aL~ost

20

However, only about 1 per cent of the patients

in the above study could not tolerate oral iron in any form.

These

problems with oral iron have led investigators to search for an iron
preparation suitable for parenteral administration.

(Other specific

indications for parenteral iron therapy will be discussed later.)
Attempts to supply iron parenterally were made as early as the
late nineteenth century.

Iron citrate and ferrous gluconate were tried

subcutaneously and intramuscularly. 17 The earliest intravenous preparations were colloidal ferric hydroxide and colloidal ferric oxide. 16
All these compounds proved to be too toxic because they liberated iol!P.c
iron into the plasma too rapidly.

The free iron exceeded the iron-

binding capacity of transferrin leading to such toxic symptoms and signs
B,S

a feeling of general warmth, palpitations, flushing of the face,

engorgement of the neck veins, nausea, vomiting, and even vascular

-7collapse. 17
The first practical parenteral iron preparation was introduced in 1947. 18

It was a saccharated iron oxide compound admin-

istered intrQvenously.

Early studies

~ii th

radioiron showed that iron

injected intravenously is rapidly utilized for hemoglobin production. 19
However, even 1-rith this substance a significant number of severe toxic
reactions occurred.
The search continued for a compound which would complex the ionic
iron securely enough to prevent toxicity and yet release it readily
for hemoglobin production.

In

1954 a new iron compound was introduced. 20

It was an iron-dextran complex which was found to be extremely well
tolerated in mice following large doses either intramuscularly or
intravenously.
Since its introduction this preparation has been the subject of
a great deal of controversy.
for a short

tL~e

It was even withdrawn from the market

in 1960 following reports that it had a carcinogenic

potential. 21
IRON-DEXTRAN (IMFERON)-i1.

Preparation and chemical properties 2,17 __ _
Dextran with molecular weight of 2000 to 20,000 is dissolved with
anbydrous

sodi~~

carbonate in hot water.

after the solution is cooled.

Ferric chloride is added

Carbon dioxide is liberated and the

resultant solution contains colloidal ferric hydroxide ...i th
cular weight dextran.
and has a pH of
cent.

101AJ

mole-

After concentration it contains 5 per cent iron

5.2 to 6.0. The sodium chloride content is 0.9 per

The complex is weakly negatively charged, isoto_ic with tissue

fluid and will not precipitate in plasma over a

ve~3

wide pH range.

-8The com:nercial preparation contains 50 mg. of elemental iron per cc.
Pharrnacology--1. Absorption
The route and rate of absorption following intramuscular injection
depend on the molecular size and local effect of the injected substance. 22
Substances of molecular weight 20,000 or more are absorbed almost exclusively by the lymphatics while those under 5,000 enter the blood stream
primarily.

Tile average molecular weight of the dextran used in the man-

ufacture of iron-dextran complex is 5,000, but the, final molecular weight
of the complex is many times this figure. 23 Following Fe59 labelled
iron-dextran injection, there is no activity or rise in seru.'1l iron for

4

to 6 hours. 17 However, stainable iron is found in the regional

lymph nodes within an hour of injection. 22

Thus, it appears that

iron-dextran is removed from the site of injection by the lymphatic
system.
About 80 to 90 per cent of an

L~jected

dose is absorbed in

48 to

72 hours with very slow absorption of the remaining matenal. 22,24

In

rabbits 98 per cent of a large intramuscular dose was absorbed after

42 days. 24 ~mphatic absorption is dependent upon the rate of lymph
flow and upon lymphatic capillary permeability both of which are increased
in an acute inflammatory reaction.

Histological stUdies have shown an

acute inflammatory reaction with degenerative changes in the muscle
fibers at the site of injection. 22

This inflammatory foeus would be

expected to enhance absorption of iron-dextran. Within

24 hours tissue

maerophages begin to appear at the injection site and show a positive
stain for iron. 22

It is interesting that the na~ber of these iron-

containing macropha,ges remains undiminished for as long as three months. 22

-9It is apparent that iron-dextran uptake by local macrophages makes
the iron no longer immediately available to the metabolically active
iron pool.
72 hours.

This macrophage uptake explains the slow absorption after
Recent studies using radioiron tagged iron-dextran have

shown that the last of multiple daily

L~jections

is consistently better

absorbed than a single injection. 25

It would appear that the initial

injection opens up the lymphatic drainage channels so that they are already working efficiently when subsequent injections are given.
2. Serum iron
In cases of acute iron poisoning, shock or coma has been reported

in 37 per cent of patients whose initial
per cent or more. 26

seru~

iron levels were 500 meg.

In patients treated with daily intra~uscular injec-

tions of 250 mg. of iron-dextran the serum iron content rose to an average of 1100 to 1200 meg. per 100 mI. on the third to fifth day with no
evidence of toxic symptoms. 17 This indicates that the iron is not in
the ionized state but is still complexed with dextran.

The iron-binding

capacity does not decrease, Le., become more saturated with ionized
iron, until about 72 hours after intrrunuscular injection.

The serum

iron content usually returns to normal values within two to three weeks
after intramuscular injection. 17 'It is of interest that serum iron
levels of 104,000 meg. per 100 mI. have been reported following intravenous infusion of iron-dextran without toxicity. 27

3. Urinary excretion
Due to the high molecular weight of the complex one would not
expect urinary loss to be significant.

Studies with radioiron support

this assumption in that less than 0.2 per cent of an intravenous dose
is lost in the urine in the first 72 hours following infusion. 23

High

...10levels of urinary iron excretion have been reported in rabbits follow.
h'
h doses
:Lng
. ~gL4

0f

. t ra,nlUSCUl
A
t roa.n. 2.8
m
ar '~on-U.ex

However, this excre-

tion occured only at doses in excess of 600 mg. Fe per kg. body weight
and did not occur at dosage levels

approxi~atLng

those used in clinical

practice, i.e., about 20 mg. Fe per kg.

4. :r.1etabolism
It is evident from the preceding discussion that the iron-dextran
complex is very stable in the plasma.

However, in order for iron to be

utilized for hemoglobin synthesis it must be in

~~

ionized state.

There-

fore, the dextran moiety must be readily split off from the iron in
order for it to be

a~

effective hematinic.

The reticuloendothelial

system would be the logical place for such degradation and, indeed,
several good studies have confirmed this assumption. 9,23,25,27 As
discussed previously, the reticuloendothelial system is important in
internal iron turnover:
(a) It removes hemoglobLn or non-viable erythrocytes
from the circulation.
(b) It splits off the iron from the heme moiety.
(0) It returns iron to the plasma for transport to

the marrow.
(d) It serves as a potential reservoir for storage
iron.
Noyes et a19 infused radioiron-tagged erythrocytes into ra~ts and
humans.

They found an almost immediate increase in surface counting

over the liver and spleen.

They found radioiron bound to transferrin

within thirty minutes after injection of the tagged red cells indicating
rapid processing by the reticuloendothelial system.

Using larger

-11-

quantities of tagged red cells, they discovered that considerable
amounts of iron were retained in the reticuloendothelial system for
twelve days prior to its release into the plasma. 9

Ingestion or

parenteral injection of iron did not cause an increased release of iron.
The only stimulus to increase the release of iron from the reticu1oendothelial system was a state of increased

erytp~opoietie

activity.

I

Surface counting in more recent studies using radioiron-tagged
iron-dextran have shown similar increases oyer liver and spleen. 23,25,27
Following intravenous infusion the tagged complex had a half-life of

2.5 to 3 days and the plasma was complet~ly cleared in 10 days. 23

It

should be noted that surface-counting patterns are slluilar after either
intravenous or intramuscular administration of the complex. 25,27

In

either case the peak radioactivity is reached about day 7 with. the
splenic rise being less marked than that of the liver.

In anemic sub-

jects, there is a gradual decrease in hepatic and splenic counts over
the next

14

days.

These patterns suggest that the liver and spleen are

the main initial storage sites of the iron-dextran complex, and that
the iron is gradually split off to subsequently appear in hemoglobin
in the circulating erythrocytes.
There is evidence to suggest that the liver and spleen handle iron
differently. 9 It is felt that iron is rapidly released by the spleen
for transport to the marrow, v.rhile liver iron is held in more slmily moving

st~res.

It has been found that the plasma clearance of iron-dextran

is related to the availability of apoferritin needed to form the storage
compound called ferritin. 23 Studies on the influence of the type of
iron compound administered on the distribution of storage iron between
ferritin and hemosiderin revealed some marked differences in distribution. 29

-12Under conditions of iron loading, rabbits

receivL~g

saccharated iron

oxide showed a marked increase in hemosiderin deposition while rabbits
receiving iron-dextran showed a more marked increase in ferritin formation.

This difference in distribution may be the result of differences

in the rate at which iron is released from the complexes.

Saccharated

iron oxide is cleared from the blood within 24 hours while iron-dextran
requires 72 hours or more.

Perhaps the slower degradation of iron-

dextran allows the liver time to synthesize sufficient apoferritin to
keep up with the liberated iron.
Regarding ferritin formation, there is a similarity between irondextran and ferrous sulfate.

Both compounds have high magnetic suscep-

tibilities as determLqed by their magnetic moments while saccharated iron
oxide and ferric hydroxide with slower ferritin production have lower
magnetic susceptibilities. 29

Further studies are needed to determine

whether this magnetic state is of significance in the rate of release
of iron from its carrier or in the rate of its incorporation into the
ferritin molecule.

5.

Effect on organ system function

Alznost all the studies done with iron-dextran, both experimental
and clinical, have measured such parameters of organ function as

Bm~,

standard liver function tests, testicular function tests, etc., and
have uniformly reported no significant changes in function after irondextran. 25,27,28 A recent study with intravenous iron-dextran investigated the effeet of the therapy on blood-grouping, coagulation, sedimentation, and hemolysis.

16 There was no change in erythrocyte sedimenta-

tion rate, blood coagulation nor was there any significant hemolysis.
ABO and Rh blood grouping and cross matching were not influenced.

-13Since the pregnant female is frequently found to be iron-deficient,
it is worthwhile to consider the placental transfer of iron and possible
effects of iron-dextran therapy on the fetus.

Normally the only source

of fetal iron is the iron circulating in maternal plasma bound to transferrin. 30 Placental transfer of iron is an active process independent
of the fetus.

Fetectomy in rats does not result in a decrease in pla-

cental uptake of iron. 31 This uptake occurs against a. concentration
gradient and retrograde transfer from fetus

to mother does not occur.

The amount of iron transported increases markedly as pregnancy pro 6Tesses.
in the rabbit 90 per cent of plasma iron turnover is directed to tho fetus
at the end of pregnancy. 30,32

No information was found in the litera-

ture on the placental response to circulating iron-dextran.

This would

appear to be an area requiring more investigation.
Clinical efficacy
Most investigators report earlier and higher reticulocytosis, but
similar responses in hematocrit and hemoglobin concentration in compro'ing oral with parenteral iron therapy. i{- Reticulocytosis may sta.rt as
early as the third day and reach a peak at

5 to 10 days of 10 to 15

per cent. 15 1rlith oral therapy the mean peak value is about one-half
the above value and is not reached until 6 to 16 days following institution of therapy.

The magnitude of response to iron therapy usually

reported is summarized in Table 2.

It should be mentinned that the rate

of response depends on the severity of the anemia.

In severe aneNia

the rate of response may exceed 2 gm per cent per week. 15

In one study

of 75 anemic vIOm8n treated with iron-dextran as a total dose intravenous
infusion, 30 cases shm.red a rise in the hemoglobin value of 1 to 2
i-.1?eferences:

7, 14, 15, 16, 17, 33, 34, 35, 36, 37, 38

gIll

. .14per cent

v-n thin 48

was 1

per cent per week. )36 This early rise, although unexpected,

gIn

hours.

(The average hemoglobin rise in this study

is possible since stainable iron is present in the marrow at 12 hours
after infusion. 39

1. Methods of administration
At the present time the manufacturer of iron-dextran recommends that
in the United States it be ad.rninistered only via the int,ramuscular route.
l{any formulas for determining dosage have been suggested, all based on
hemoglobin deficit, body weight and status of iron stores.
easiest rule to remember is as follows:

Probably the

250 mg of iron (5 ml of iron-

dextran solution) for each gram per cent of hemoglobin deficiency. 17
Dosages greater than 5 ml in each buttock per day result in appreciable
muscle soreness.

To prevent brovm staining of the skin at the site of

Lnjection, a Z-track technique with a two or three inch needle is used.
It should be remembered that 20 to

25 per cent of an intramuscular dose

is not readily available for hemoglobin production because of poor
absorption after the first 72 hours.
There are certain disadva,ntages to the intramuscuh.r administration
of iron-dextran that make the intravenous route more appealing such as:

(1) patients tire of having repeated painful injections, (2) difficulty
of administration in asthenic patients with little muscle mass, (3) possibility of brown stainingef the sldn,and (4) rare patients with idiopathic thrombocytopenic purpura or other

bleedL~g

disorders who luay have

severe tissue bleeding after intramuscular injections.

Therefore, the

total dose infusion technique vIas introduced in 1963. 40 Actually the
complex Il\l'aS found to be the least toxic of all iron preparations 1.fhen
given intr<l.venously to animals as early as 1955. 24,38

The LD50 following

-15intravenous infusion in mice is over 1,000 mg of iron per kg body
weight.

46

Basu40 reported that work in laboratory animals has shown

tha,t iron-dextran complex, in company \vith physiological iron such as
ferritin, has a powerful general adrenolytic effect, causing hy;,ootension, when introduced rapidly into the blood, but this effect does not
appear 'fihen the complex is diluted and given slowly.

Maryhasin and

Wallerstein39 have used undiluted iron-dextran intravenously in doses
up to 3000 mg LD 45 patients.
in this study.

No serious untoward effects were observed

One patient developed chills and mild abdominal cramps

8 hours after injection.

However, :nost investigators have chosen to

a&ninister the iron-dextran diluted in 5 per cent glucose or normal
saline in various concentrations, usually about 10 to

25

ml diluted to

500 cc. 16,23,27,36,3 8,40,41 l10st investigators report a hemoglobin rise
of 1 to 2 gm per cent per week which is comparable with results in successful

oral~ntramuscular

therapy.

In order to prevent severe reactions

certain precautions need to be taken into consideration before selecting
patients for this form of therapy.
(a) Patients with cardiac disease should be excluded
to prevent overloading the circulation and cardiac failure.
(b) It has been found that patients 'flith active pulmonary
disease have a higher incidence of bronchospasm after the
intravenous

admL~istration

of iron.

(c) Severe reactions have been reported in cases of
toxemia of pregnancy 'irith

albu!tlL~uria

so that patients 'l"lith

uncon'crolled toxemia and kidney disease should be excluded.
(d) Severe retl,ctions have also been reported i f intravenous or intramuscular iron-dextran is folloi'led 10 to 20

-16days later \-vi th a massive intravenous infusion.
(e) Normal saline has been reported to be better
tolerated than 5 per cent glucose for the infusion of
iron-dextran complex. 36
(f) Most workers suggest using a test dose by
ri.mning the infusion very slowly for the first

fe1rT

minutes.

If the patient complains of giddiness, chest pain, cough,
or any other discomfort the infusion is discontinued.
2. Indications for parenteral iron
For the great majority of cases of iron-deficiency anemia, parenteral iron offers no advantages over oral iron therapy.

However there

are certaLn valid indications for parenteral iron and these should be
enmr.rnerated.
(a) l1alabsor;?tion of iron from the gastrointestinal
t:cact as in:
(1) Total or SUbtotal gastrectomy
(2) Intestinal disease such as sprue
(3) Steatorrhea
(b) Proved intolerance to oral iron.
(c) Inability to be sure that oral medication is
taken as in:
(1)

I~~ates

of institutions

(2) Children
(3) Patients from low socio-economic groups
(4) Geriatric patients

(d) Selected chronic hemorrhagic states such as
congenital telangiectasia. 42

-17Adverse effects and toxicity
The a.dverse effects in 60 patients treated l"i th intramuscular
iron are sThl1Illarized as follows:

34

NlL"'!1ber of
Patients

COI!l"nent

Local discomfort------------All-----------------Rarely lasted more than
10 to lS minutes
Pain radiating down
back of leg---------------3------------------Not likely due to sciatic
nerve irritation, may be
related to volwne of intramuscular injection
Brown staining of skin-------5------------------Hinimized by using Z-track
tec11l1ique d-o.ring injection
Episode of giddiness
and malaise for 1 hour
after injection-----------l------------------The hematocrit in this
patient was only 15
Dyspnea, paresthesias,
and epigastric pain occuring 24 hours after injection--l-----------------Nay have represented anxiety and effects of severe
anemia
Occa.sional transient allergic reactions have been reported such as
urtic('U'ia, arthralgia., lJrmphadenopathy, nausea, vomiting, headache and
fever.

43,44,45,46,h7

These reactions usually respond well to supportive

medication and antihistamines.

An interesting finding ,-vas reported by

BovJrnan 35 in anemic children treated 1tJith intramuscular iron-dextrcm.
In tr~ee patients with severely depressed hemoglobin levels
gIn

(1.9 to 2.6

per cent), iron-dextran thera.py resulted in a leukoerythroblastic

response as noted on periphera.l smear.

The granulocytic leukccytosis

was not unlike that of chronic granulocytic leukemia \-li th band forms,
meta.'Uyelocytes, myelocytes, occasional progranulocytes and rare myeloblasts
appearing on peripheral smear.

These responses t-rere transient and

-18disappeared by the fourteenth day_
Studies of acute and chronic toxicity in ani.'11als have shown irondextran to be the least toxic of all the iron preparations.
toxicity findings were mentioned previously.

Acute

In determining the chronic

toxicity of the preparation, Juice, rats, and guinea-pigs have been given
total doses of more -than 30 times the usual clinical dose and, more than
a year later, have

Sh01fv'TI

no ill-effects whatsoever e 24,38

In antigeni-

ci,ty studies, there were no signs of al1aphylaxis in guinea-pigs when
the challenging dose was ac1llinistered 14 days after sensitization \..rith
iron-dextran. 24

In the salle report no serurrl antibodies were produced

in rabbits "'"lhich would react ,·lith either dextran or iron-dextran. 24
Karlefors and ~Jorden17 found that reactions were most COiTh'110n on
the fourth day after the initial intramuscular injection.

Since skin

tests with iron-dextran were negative and complement fixation studies
and precipitin reactions were equivocal, they felt that the theory of
a sensi tiz ing mechanism could not be supported.

It was their opinion

that most of the reactions ,iere due to the toxic effect of ionic iron
split off in the reticuloendothelial system.
Severe reactions and even several deaths following iron-dextran
therapy have been reported. 43,44,45,46,47

Tne more disturbing

reactions include headache, vomiting, and fever 17 , recurrent arthralgia
and cellulitis 43 , transient shock-like conditions44, fever with painful
enlargement of the inguinal l~oh nOdes 45 , encephalopathy46, joint
effusion46 , and one case of cerebral hemorrhage leading to death. 46
The cause of death was "ventricular hemorrhage most probably due to
acute

h~vpertension

kidney." 46

resulting from the toxic effects of iron on the

Iron was deposited in the endothelial lining of the

-19capillary loops of almost all the glomeruli.

Under conditions of

iron loading with iron-dextran, rabbits died vrith kidney findings similar to the case above. 28

One study showed that reactions i-iere more

common in pregnant irwmen th:m in the non-pregnant.

46

They also found

that reactions were more common and severe 1{hen the anemia was dimorphic
and when pre-ec1runpsia was present.

The incidence of reactions did not

seem to bear any relationship to the severity of anemia, the dosage of
iron-dextran, and the serum protein level.

It would seem likely that

some of the reactions reported are allergic in nature

Ci!'

due to some hyper-

sensitivity, but proof awaits further investigation.
Intensive and prolonged adLunistration of iron parenterally in
ani~als

results in siderosis of the liver, spleen, inguinal lYMPh nodes,

and occasionally of lymph nodes elset-There. 28

This vIas not accompanied

by any detectable disturbance of liver function.
by itself does not appear to induce tissue damage.

Severe iron overload

48

However, studies

on ~on-induced liver damage support the conclusion that a liver loaded
;'7i th iron is more vulnerable to the action of toxic agents or deficient
diets. 48,49,50,51 After 40 weeks of iron-dextran injections in monkeys
the liver was found to contain much iron in macropha.ges and also in
parenchymal cells, but no histological evidence of cirrhosis or of any
pre-cirrhotic changes was observed.

52

Carcinogenic potential

In 1959, Rich~ond53 reported sarcoma production at the site of injection of iron-dextran in rats.

This effect has been well substantiated

by others in mice and rats and is now undisputed. 21

However, most of

these studies have been done loii th larger doses than those used clinically
in relation to body weight.

In 1960, Robinson et a154 reported a hmnan

-20case of possible association of malignant neoplasm with iron-dextran
injection.

Four years after a short series of iron-dextran injections

in the left deltoid area of a
noted.

7L~

year old 'VJhite female, a, soft mass ,"las

The initial pathological diagnosis ltVas undifferentiated sarcoma.

There was a :narked difference in the histologic appearance of the tumor
and those produced in rats.

Since that

tL~e

slides of this tumor have

been sent to many pathologists in the U.S.A. and Canada.
a great deal of variation of opinion as to the type
the Llajority agreed that it was malignant. 47

There was

of tumor although

Roe and Carter 55 tested

the assulllption that sarcomas were produced only at very high doses.
They found sarcomas at the site of injection in 8 out of 16 rats receiving 16 injections of 0.75 mlof iron-dextran at weekly intervals.
128 rats receiving 2 injections of 0.75 ml of iron-dextran only
sarcomas were found.

In

5

The most malignant tumors were found in ani..'1lals

receiving the highest doses.

It should be pointed out that the animals

on the lowest dosages received an amount equal to 375 mg per kg body
weight which is still considerably more than the average clinical dose
of 2') mg per kg.

The majority of tUt'llors appeared only after 400 to

600 days follmving injections.

It has been suggested that the latent

period before the appearance of iron-dextran sarcomas may be as long as
one-quarter to one-third of the life-span of the species in question.

52

Monkeys failed to develop tumors after as many as 40 weekly injections
of 0.25 ml iron-dextran.

They \vere observed for as long as a year, but

this period of observation may still have been too short.

In view of

the long latent period between exposure to iron-dextran and the appearance of sarcomas we may have to wait

15

to 20 years for a useful answer

to the question of possible carcinogenic effect of iron-dextran in man.

-21S~~ary

and conclusions

After a brief review of iron metabolism including information
from some of the, newer ferrokinetic studies, the physiologic and
pharmacoloisic effects of iron-dextran \,rere discussed.

It would

appear that in the majority of cases of iron deficiency oral iron
therapy is indicated because of the possible adverse effects and toxic
reactions from iron-dextran.

Most investigators report similar clinical

responses with oral or parenteral iron therapy.

Specific indications

for parenteral iron therapy were discussed.
Iron deficiency in the United Ste.tes is probably [!lost C0111110n in
pregnant women.

A higher incidence of toxic reactions following iron-

dextran therapy has been reported in pregnant than in non-pregnant
-vwmen.

Very little information is available on the effects of iron-

dextran on the fetus and placenta.

Since considerable nm!lbers of

pregnant i<lOmen are receiving iron-dextran, studies on placental
transfer of this substance should be done.
The total dose infusion technique introduced recently offers
several advantages over intramuscular injections.

Since the reported

incidence of reactions seems to be no greater with this method, it
deserves further investigation.
A great variety of reactions to iron-dextran have been reported.
Some of these reactions are undoubtedly due to the toxic effect of
ionic iron split off too rapidly by the reticuloendothelial system.
Others seem to ha.ve an allergic or hypersensitivity basis.

Further stu-

dies in this area seem indicated.
The question of possible carcinogenic effect of iron-dextran in
man is unresolved.

Since the latent period may be as long as one-third

-22-

of the life span of the species, we may have to wait
years for a useful answer.

15

to 20

-23-

Figure 1:

Hemolysis

Iron Hetabolism

R.B.C. Procuction

R.B.C.

0.8% R. B.C.
daily

f

2500 mg

"

0.8% R.B.C.
daily

,~

(R.E. System)
20 mg daily

20 mg daily

Absorption

Excretion

1 to 2 mg daily

Plasma Pool
4 mg

)

5 mg

1 to 2 rag daily-

)

daily

\

..
Body Stores
1000 mg

. 11yoglobin
Resp. Enzymes
300 mg

From. Conrad, 11. E.: Maryland Med. J.,

17:76, 1968.

-24Table 1
Intraluminal Factors

Increase Absorption

Decrease Absorption

DIET/I....,'tY

1. Precipitatin« chelates
X
X
X
X

a. carbtnate
b. phos hate
c.

Phlate

d. oxa ate

X

2. Sugars

3. Amino tids

4.

.

Other ldUCiUg substances
e.g. Ascorbic acid

X
X

GASTRIC
I
I

1. HCl

I
I

X

I

2. IntrinlC factor

X

3. Gastrof rrin

X

I

BILE
1. Ascorba e

X

2. Glutath ione

X

PftJICREAS

1. Bicarb nate

X

-25-

Table 2
Response to Iron Therapy

DOSE
IRON PREPARATION

(mg~

NO. OF
SUBJECTS

INITIAL
HEHOGLOBIN
(gm
•

of'l
/01

INCRE..4.SE
PER
D..ltY
(gm %)

TOTAL
HEI10GlOBIN
PRODUCTION
eX NORlvIAL}

I..l1tramuscular:
0.28

2.9

11

0.26

2.8

180

10

0.25

4. F'errous Gluconate 220

10

0.25

8

0.26

1. Iron-Dextran

250

2. Iron-Sorbitex

100

Oral:
3. Ferrous Sulfate

5. Ferrous Fumarate

200

From Scott, D. E. et al:
30:679, 1967.

Obstet. Gynec.
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